These findings align with preclinical evidence highlighting the Th17/IL-17 axis as a central driver of MG immunopathology (19, 21, 22), where IL-17 promotes B-cell dysregulation, autoantibody production, and neuromuscular junction inflammation (23). This evidence concerns the gene IL17A and myasthenia gravis.